These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1537736)

  • 1. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum.
    Rupp H; Wahl R; Hansen M
    J Appl Physiol (1985); 1992 Jan; 72(1):352-60. PubMed ID: 1537736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.
    Rupp H; Schulze W; Vetter R
    Am J Physiol; 1995 Sep; 269(3 Pt 2):R630-40. PubMed ID: 7573566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.
    Vetter R; Rupp H
    Am J Physiol; 1994 Dec; 267(6 Pt 2):H2091-9. PubMed ID: 7810710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sarcoplasmic reticulum phosphorylation.
    Vetter R; Kott M; Rupp H
    Eur Heart J; 1995 May; 16 Suppl C():15-9. PubMed ID: 7556265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
    Rupp H; Vetter R
    Br J Pharmacol; 2000 Dec; 131(8):1748-56. PubMed ID: 11139455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dietary lipid manipulation on hepatic mitochondrial phospholipid fatty acid composition and carnitine palmitoyltransferase I activity.
    Power GW; Yaqoob P; Harvey DJ; Newsholme EA; Calder PC
    Biochem Mol Biol Int; 1994 Oct; 34(4):671-84. PubMed ID: 7866292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etomoxir improves left ventricular performance of pressure-overloaded rat heart.
    Turcani M; Rupp H
    Circulation; 1997 Nov; 96(10):3681-6. PubMed ID: 9396471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions.
    Rupp H; Elimban V; Dhalla NS
    Mol Cell Biochem; 1994 Mar; 132(1):69-80. PubMed ID: 8078510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor.
    Rupp H; Elimban V; Dhalla NS
    FASEB J; 1992 Mar; 6(6):2349-53. PubMed ID: 1531968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of verapamil on some subcellular defects in diabetic cardiomyopathy.
    Afzal N; Pierce GN; Elimban V; Beamish RE; Dhalla NS
    Am J Physiol; 1989 Apr; 256(4 Pt 1):E453-8. PubMed ID: 2523196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of etomoxir on 24-h substrate oxidation and satiety in humans.
    Hinderling VB; Schrauwen P; Langhans W; Westerterp-Plantenga MS
    Am J Clin Nutr; 2002 Jul; 76(1):141-7. PubMed ID: 12081827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial contractility after infarction and carnitine palmitoyltransferase I inhibition in rats.
    Günther J; Wagner K; Theres H; Schimke I; Born A; Scholz H; Vetter R
    Eur J Pharmacol; 2000 Oct; 406(1):123-6. PubMed ID: 11011043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target.
    Zarain-Herzberg A; Rupp H
    Expert Opin Investig Drugs; 2002 Mar; 11(3):345-56. PubMed ID: 11866664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.
    Luiken JJ; Niessen HE; Coort SL; Hoebers N; Coumans WA; Schwenk RW; Bonen A; Glatz JF
    Biochem J; 2009 Apr; 419(2):447-55. PubMed ID: 19138173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carnitine palmitoyl transferase-I inhibition is not associated with cardiac hypertrophy in rats fed a high-fat diet.
    Okere IC; Chandler MP; McElfresh TA; Rennison JH; Kung TA; Hoit BD; Ernsberger P; Young ME; Stanley WC
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):113-9. PubMed ID: 17201745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
    Schmitz FJ; Rösen P; Reinauer H
    Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of sucrose-induced changes in cardiac phenotype.
    Rupp H; Wahl R; Maisch B; Hansen M
    Pflugers Arch; 2002 Oct; 445(1):32-9. PubMed ID: 12397384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of carnitine acyltransferase inhibitors on the performance and metabolism of rat cardiac muscle.
    Reinauer H; Adrian M; Rösen P; Schmitz FJ
    J Clin Chem Clin Biochem; 1990 May; 28(5):335-9. PubMed ID: 2380671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl palmoxirate increases Ca2+-myosin ATPase activity and changes myosin isoenzyme distribution in the diabetic rat heart.
    Dillmann WH
    Am J Physiol; 1985 May; 248(5 Pt 1):E602-6. PubMed ID: 3158215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.